克隆性造血与心血管疾病及癌症的关联综述
本综述探讨克隆性造血(CH)作为癌症与心血管疾病(CVD)潜在统一因素的关联。CH患病率随年龄增长而升高,与血液恶性肿瘤风险及CVD风险增加相关,炎症可能是其机制之一。CH可能为心脏肿瘤学精准医学提供新途径。
要点
- CH患病率随年龄增长而升高,90岁以上人群可达15%至20%以上。
- CH携带者心血管疾病风险增加2至4倍,独立于传统危险因素。
- CH与CVD的关联可能由炎症介导,且可能影响癌症幸存者的CVD风险。
核心结论
- CH是一种前恶性状态,携带者血液恶性肿瘤风险增加,但多数携带者不会发展为恶性肿瘤。
- CH通过可能的炎症机制增加CVD风险,并可能贡献于癌症幸存者的CVD风险,但该假说需验证。
研究设计与样本
- 综述,讨论CH与癌症及CVD的关联,CH作为潜在统一因素。
主要发现
- CH患病率从40岁以下人群的不到1%到90岁及以上人群的15%至20%以上不等,取决于测序深度、诊断标准和患者年龄。
- CH与血液恶性肿瘤年绝对风险0.5%至1.0%相关,并与冠状动脉疾病、卒中和CVD死亡风险增加2至4倍相关,独立于传统心血管危险因素。
- CH对CVD的相对风险与传统心血管危险因素相似。
- 实验研究提示CVD与CH的关联是因果性的,炎症是潜在机制之一。
- CH与癌症幸存者CVD之间可能存在关联,但支持数据有限。
临床怎么用
- 随着先进测序技术的可用性,CH可能为心脏肿瘤学领域的精准医学铺平道路。
局限性
- 支持CH与癌症幸存者CVD关联的数据目前有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clonal hematopoiesis (CH) has been recently described as a novel driver for cancer and cardiovascular disease (CVD). Clonal hematopoiesis is a common, age-associated disorder marked by expansion of hematopoietic clones carrying recurrent somatic mutations. Current literature suggests that patients with CH have a higher risk of subsequent hematological malignant conditions and mortality attributable to excess CVD. This review discusses the association of cancer with CVD with CH as a potential unifying factor. OBSERVATIONS: The prevalence of CH varies based on the sequencing depth, diagnostic criteria, and patient age and ranges from less than 1% in those younger than 40 years to more than 15% to 20% in those 90 years and older. Clonal hematopoiesis is associated with a 0.5% to 1.0% absolute annual risk of hematological malignant condition and a 2-fold to 4-fold higher risk of coronary artery disease, stroke, and CVD deaths, independent of traditional cardiovascular risk factors. In fact, CH appears to have a relative risk similar to that of traditional cardiovascular risk factors for CVD. Experimental studies suggest that the link between CVD and CH is causal, with inflammation as 1 potential mechanism. There may be also a link between CH and CVD in survivors of cancer; however, data to support this association are currently limited. CONCLUSIONS AND RELEVANCE: Clonal hematopoiesis represents a premalignant state, with carriers having an increased risk of hematological malignant conditions. Although most carriers will not develop a malignant condition, CH confers an increased risk of CVD, possibly via inflammation. Clonal hematopoiesis may also contribute to CVD in survivors of cancer, although this hypothesis requires validation. Clinically, as advanced sequencing techniques become available, CH may pave the way for precision medicine in the field of cardio-oncology.
引用
- Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review. JAMA Cardiol. 2019. PMID: 30865214. doi:10.1001/jamacardio.2019.0302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。